-
公开(公告)号：US20210069100A1
公开(公告)日：2021-03-11
申请号：US17024148
申请日：2020-09-17
Inventor： Minglin Ma , Daniel G. Anderson , Robert S. Langer , Omid Veiseh , Joshua Charles Doloff , Delai Chen , Christian J. Kastrup , Arturo Jose Vegas
Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
-
公开(公告)号：US20200016085A1
公开(公告)日：2020-01-16
申请号：US16584170
申请日：2019-09-26
Inventor： Arturo J. Vegas , Joshua C. Doloff , Omid Veiseh , Minglin Ma , Robert S. Langer , Daniel G. Anderson
IPC: A61K9/50 , C08B37/00 , A61K35/39 , C12N5/00 , C12N5/071 , A61K9/00 , A61L29/08 , A61L31/10 , A61L33/08
Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
-
Patent Agency Ranking
公开(公告)号：US20190083495A1
公开(公告)日：2019-03-21
申请号：US16081654
申请日：2017-04-04
Applicant: Massachusetts Institute of Technology
Inventor： Joshua C. Doloff , Shady Farah , Omid Veiseh , Arturo J. Vegas , Robert S. Langer , Daniel G. Anderson
IPC: A61K31/519 , A61K31/4709 , A61K31/4439 , A61K31/5377 , A61K31/416 , A61K31/444 , A61K31/496 , A61K31/404 , A61K31/553 , A61K31/551 , A61K31/5025
Abstract: Described herein are methods of preventing or reducing fibrosis comprising administering CSF1R inhibitors, coating formulations comprising CSF1R inhibitors, coatings comprising CSF1R inhibitors for implantable medical devices, CSF1R inhibitor coated implantable medical devices, as well as corresponding embodiments comprising additional agents.
-
公开(公告)号：US20170355799A1
公开(公告)日：2017-12-14
申请号：US15621391
申请日：2017-06-13
Inventor： Omid Veiseh , Volkan Yesilyurt , Arturo Vegas , Joshua Doloff , Daniel G. Anderson , Robert S. Langer
IPC: C08F230/02 , A61L29/08 , A61L27/16 , A61L27/54 , A61K35/12 , A61K9/50 , A61L27/38 , C08F220/38 , A61L29/16 , A61L29/04 , A61L31/04 , A61L31/10 , A61L27/56 , A61L31/16 , A61L27/34 , A61L27/52
Abstract: Zwitterionic polymers or biocompatible polymers with improved properties for cell encapsulation, coating of devices, or a combination thereof are described. The biocompatible polymer contains a zwitterionic monomer, a monomer with a reactive side chain, and optionally another hydrophobic monomer or a neutral hydrophilic monomer. The zwitterionic polymers are cross-linked with a cross-linker via covalent bond to form a zwitterionic hydrogel in the presence of cells. Also provided, are methods of making and using the zwitterionic polymers.
-
公开(公告)号：US20170239397A1
公开(公告)日：2017-08-24
申请号：US15588475
申请日：2017-05-05
Inventor： Arturo J. Vegas , Joshua C. Doloff , Omid Veiseh , Minglin Ma , Robert S. Langer , Daniel G. Anderson
IPC: A61L29/08 , A61L33/08 , A61K9/00 , C07D487/04 , A61K35/39 , C12N5/00 , A61K9/50 , C12N5/071 , A61L31/10 , C08B37/00
Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
-
公开(公告)号：US20170226232A1
公开(公告)日：2017-08-10
申请号：US15341110
申请日：2016-11-02
Inventor： Arturo J. Vegas , Joshua C. Doloff , Omid Veiseh , Minglin Ma , Robert S. Langer , Daniel G. Anderson
Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
-
公开(公告)号：US20170095514A1
公开(公告)日：2017-04-06
申请号：US15379718
申请日：2016-12-15
Inventor： Minglin Ma , Daniel G. Anderson , Robert S. Langer , Omid Veiseh , Arturo Jose Vegas , Joshua Charles Doloff , Delai Chen , Christian J. Kastrup
CPC classification number: A61K9/0024 , A61K9/4833 , A61K9/4866 , A61K9/5036 , A61K9/5078 , A61K9/5089 , A61K35/39 , A61K45/06 , A61K2035/126 , A61K2035/128 , B01J13/046
Abstract: Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
-
-
-
-
-
-
Search Results
37
records
(took 0.052 seconds)
